Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368195 | 1.00 | IDO1 (0.48) | IDO1PDPK1PLAUTAS1R3TAS1R1 | |
| Hydrochloric Acid SCHEMBL8541821 | 0.98 | IDO1 (0.50) | IDO1PDPK1PLAUTAS1R3TAS1R1 | |
| SCHEMBL18408553 | 0.79 | DRD2 (0.53) | IDO1PDPK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1261931 | 0.79 | DRD2 (0.53) | IDO1PDPK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL599176 | 0.79 | KDM1A (0.47) | HTR2A | |
| SCHEMBL11450268 | 0.79 | IDO1 (0.52) | IDO1PDPK1PLAUHTR2ARET | |
| SCHEMBL9062798 | 0.79 | KDM1A (0.47) | HTR2A | |
| SCHEMBL599175 | 0.79 | KDM1A (0.47) | HTR2A | |
| SCHEMBL11450267 | 0.79 | IDO1 (0.52) | IDO1PDPK1PLAUHTR2ARET | |
| SCHEMBL9776879 | 0.79 | IDO1 (0.52) | IDO1PDPK1PLAUHTR2ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208442-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006013210-A2 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2006-02-09 | — | — | WO | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
| EP-0179667-B1 | N6-SUBSTITUTED ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4791103-A | HYPOTENSIVE AGENTS, PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | IDO1 1274/4885PDPK1 4130/4885PLAU 4871/4885 |
| US-20240067614-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, CXCR2 | IDO1 2748/4885PDPK1 1983/4885PLAU 3747/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | IDO1 3619/4885PDPK1 3904/4885PLAU 4791/4885 |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | IDO1 193/4885PDPK1 1084/4885PLAU 4133/4885 |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, QTRT2 | IDO1 246/4885PDPK1 2892/4885PLAU 4754/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | IDO1 85/4885PDPK1 3017/4885PLAU 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.